Dihydroergotoxine Methanesulphonate en es it fr

Dihydroergotoxine Methanesulphonate Brand names, Dihydroergotoxine Methanesulphonate Analogs

Dihydroergotoxine Methanesulphonate Brand Names Mixture

  • No information avaliable

Dihydroergotoxine Methanesulphonate Chemical_Formula

C33H45N5O5

Dihydroergotoxine Methanesulphonate RX_link

No information avaliable

Dihydroergotoxine Methanesulphonate fda sheet

Dihydroergotoxine Methanesulphonate msds (material safety sheet)

Dihydroergotoxine Methanesulphonate Synthesis Reference

No information avaliable

Dihydroergotoxine Methanesulphonate Molecular Weight

591.741 g/mol

Dihydroergotoxine Methanesulphonate Melting Point

No information avaliable

Dihydroergotoxine Methanesulphonate H2O Solubility

No information avaliable

Dihydroergotoxine Methanesulphonate State

Solid

Dihydroergotoxine Methanesulphonate LogP

2.615

Dihydroergotoxine Methanesulphonate Dosage Forms

Capsule; Liquid; Powder; Powder for solution; Solution; Syrup; Tablet

Dihydroergotoxine Methanesulphonate Indication

For use as an adjunct therapy for patients with dementia

Dihydroergotoxine Methanesulphonate Pharmacology

Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.

Dihydroergotoxine Methanesulphonate Absorption

Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.

Dihydroergotoxine Methanesulphonate side effects and Toxicity

Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.

Dihydroergotoxine Methanesulphonate Patient Information

No information avaliable

Dihydroergotoxine Methanesulphonate Organisms Affected

Humans and other mammals